Please log in
You must be logged in to send the contact request.
Manage stand orders
Select Option
ReLIA Biological Engineering (Shanghai) Co., Ltd.
5th, Floor, Building 4, Zhongshan North Road, Hongkou District,
200437
Shanghai
China
China
Submit your contact details
Provide your contact details to the exhibitor. Optionally, you may also add a personal message.
Your name, phone number, and e-mail address are subject to the submission of personal data. Messe Düsseldorf GmbH expressly points out that for a data transmission into third countries, for which no adequacy decision of the EU-commission is on hand certifying an adequate level of protection of personal data, it is not ensured that there are appropriate safeguards for the protection of personal data on hand.
An error has occurred
Please check your internet connection or try again later.
Message has been sent
Your message to the exhibitor was sent successfully.
Contact
Our range of products
Product categories
- 03 Diagnostic tests
- 03.02 Immunochemistry testing, immunology testing
- 03.02.02 Diagnostic rapid tests
Diagnostic rapid tests
About us
Company details
Since its foundation in 2001, ReLIA Biotech has been at the forefront of research in point of care testing technologies, with it’s primary research and development centre located in Silicon Valley, California. Currently, it holds its Asian Pacific headquarters at the Shekou Free Trade Zone, Shenzhen, as well as large scale production and R&D centers in Shenzhen and Jiangsu.
Under the guidance of Dr. Willian J. Rutter, our company’s founder, ReLIA has adhered to a diligent attitude towards research. We mold modern developments into technological advancement/systems, which promote rapid diagnostic services and improve the health and wellbeing of patients whilst simultaneously reducing medical costs.
Currently, the company focuses on two categories of rapid detection systems: The multi-functional immunoassay system and immunofluorescence detection system. Both of these systems cover the detection of biomarkers for cardiovascular, acute kidney injury and inflammatory related conditions.
Under the guidance of Dr. Willian J. Rutter, our company’s founder, ReLIA has adhered to a diligent attitude towards research. We mold modern developments into technological advancement/systems, which promote rapid diagnostic services and improve the health and wellbeing of patients whilst simultaneously reducing medical costs.
Currently, the company focuses on two categories of rapid detection systems: The multi-functional immunoassay system and immunofluorescence detection system. Both of these systems cover the detection of biomarkers for cardiovascular, acute kidney injury and inflammatory related conditions.